Fig. 1From: Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndromeDistribution of ticagrelor platelet inhibiting rate measured by TEG in ACS patients. A and B represent the distribution of ADP% measured by TEG in derivation and validation group, respectively. C represent the distribution of ADP% in all included patients. ACS: acute coronary syndrome; ADP%: ADP-induced platelet inhibition rate; TEG: thromboelastographyBack to article page